综合信息
查看供应
物理化学性质
| 密度 | 1.349 |
产品用途
Dapagliflozin (rINN/USAN)is an experimental drug being studied by Bristol-Myers Squibb in partnership with AstraZeneca as a potential treatment for type 1[1] and 2 diabetes. Although dapagliflozin's method of action would operate on either type of diabetes or other conditions resulting in hyperglycemia, the current clinical trials specifically exclude participants with Type 1 diabetes.
安全术语
风险术语
上游原料
5-bromo-2-chlorobenzoic acid5-Bromo-2-chlorobenzoyl chloridePhenetole; Ethoxybenzene; Ethyl phenyl ether(5-Bromo-2-chlorophenyl)(4-ethoxyphenyl)methanone4-(5-Bromo-2-chlorobenzyl)phenyl ethyl etherD-Gluconolactone；GLUCONIC ACID DELTA-LACTONE；D-(+)-GLUCONO-1,5-LACTONE;DELTA-LACTONE;GLUCONIC ANHYDRIDE;GLUCONIC-D-LACTONE2,3,4,6-Tetrakis-O-trimethylsilyl-D-gluconolactone; D-2,3,4,6-Tetrakis-O-(trimethylsilyl)-gluconic acid delta-lactone; (3R,4S,5R,6R)-3,4,5-Tris[(trimethylsilyl)oxy]-6-[[(trimethylsilyl)oxy]methyl]tetrahydropyran-2-oneMethyl 1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-alpha-D-glucopyranoside
